STAT1 and myeloproliferative neoplasm: Interestingly, studies investigating the effects of ruxolitinib treatment in patients with STAT1 gain-of-function mutations reported higher levels of STAT5 phosphorylation post-treatment, and the perforin expression appeared to be restored, contradictory to the results reported in MPN patients [141].